Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.73 |
| ▸ | RARB | P10826 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18682480 | 1.00 | TP53 (0.75) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL6132822 | 1.00 | TP53 (0.75) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL18682414 | 0.95 | RARB (0.77) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL7332700 | 0.95 | RARB (0.77) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL7329413 | 0.95 | RARB (0.77) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL7340390 | 0.95 | RARB (0.77) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL2882011 | 0.95 | PLA2G4B (0.70) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL8747416 | 0.93 | RARB (0.74) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL209561 | 0.91 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL14097198 | 0.91 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
| EP-1173472-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | TP53 3972/4885TSHR 3849/4885PLA2G4B 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.